• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

吉非替尼的皮肤副作用及经表皮水分流失：11例患者的研究

Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients.

作者信息

Chandra Franky, Sandiono Dendi, Sugiri Unwati, Suwarsa Oki, Gunawan Hendra

机构信息

Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.

出版信息

Dermatol Ther (Heidelb). 2017 Mar;7(1):133-141. doi: 10.1007/s13555-016-0163-0. Epub 2016 Dec 21.

DOI:10.1007/s13555-016-0163-0
PMID:28004308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5336432/
Abstract

INTRODUCTION

Cutaneous side effects caused by epidermal growth factor receptor (EGFR) inhibitors occurred in 45-100% of patients which may lead to therapy modification or interruption. This study aimed to evaluate cutaneous side effects and transepidermal water loss (TEWL) values in non-small cell lung carcinoma (NSCLC) patients who received gefitinib EGFR inhibitor.

METHODS

A descriptive observational study with cross-sectional design and a consecutive sampling method was conducted from 1 February to 4 March 2016. Eleven NSCLC patients with EGFR mutation who visited the Hemato-Oncology Clinic/Internal Medicine Department, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia, were assessed through history taking, physical examination, and TEWL examination using Tewameter.

RESULTS

Ten of the eleven patients experienced cutaneous side effects. The most frequently observed was xerosis cutis (8/10 patients), followed by acneiform eruptions (7/10 patients), and paronychia (3/10 patients). None of these patients experienced hair changes, mucositis, or drug hypersensitivity. Mean TEWL value of these patients was higher than normal (11.205 ± 1.881 g/m/h).

CONCLUSIONS

Patients who received gefitinib EGFR inhibitor experienced cutaneous side effects including xerosis cutis, acneiform eruptions, and paronychia, and have mean TEWL values higher than normal. Therefore, it might affect the skin barrier function.

摘要

引言

表皮生长因子受体（EGFR）抑制剂引起的皮肤副作用发生在45%-100%的患者中，这可能导致治疗调整或中断。本研究旨在评估接受吉非替尼（一种EGFR抑制剂）治疗的非小细胞肺癌（NSCLC）患者的皮肤副作用和经表皮水分流失（TEWL）值。

方法

采用横断面设计和连续抽样方法进行描述性观察研究，研究时间为2016年2月1日至3月4日。对11例EGFR突变的NSCLC患者进行了评估，这些患者前往印度尼西亚万隆哈桑·萨迪金综合医院血液肿瘤诊所/内科就诊，通过病史采集、体格检查以及使用皮肤水分流失仪进行TEWL检查。

结果

11例患者中有10例出现皮肤副作用。最常观察到的是皮肤干燥（8/10例患者），其次是痤疮样皮疹（7/10例患者）和甲沟炎（3/10例患者）。这些患者均未出现毛发改变、口腔黏膜炎或药物过敏。这些患者的平均TEWL值高于正常水平（11.205±1.881克/平方米/小时）。

结论

接受吉非替尼EGFR抑制剂治疗的患者出现了包括皮肤干燥、痤疮样皮疹和甲沟炎在内的皮肤副作用，且平均TEWL值高于正常水平。因此，这可能会影响皮肤屏障功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7020/5336432/44e95dbe0257/13555_2016_163_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7020/5336432/9673f2878935/13555_2016_163_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7020/5336432/99c7298e71c4/13555_2016_163_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7020/5336432/e08939a7b77b/13555_2016_163_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7020/5336432/44e95dbe0257/13555_2016_163_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7020/5336432/9673f2878935/13555_2016_163_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7020/5336432/99c7298e71c4/13555_2016_163_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7020/5336432/e08939a7b77b/13555_2016_163_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7020/5336432/44e95dbe0257/13555_2016_163_Fig4_HTML.jpg

相似文献

1
Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients.吉非替尼的皮肤副作用及经表皮水分流失：11例患者的研究
Dermatol Ther (Heidelb). 2017 Mar;7(1):133-141. doi: 10.1007/s13555-016-0163-0. Epub 2016 Dec 21.
2
Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex.表皮生长因子受体抑制剂的皮肤副作用：“PRIDE”综合征
Indian J Dermatol. 2014 May;59(3):271-4. doi: 10.4103/0019-5154.131398.
3
[Cutaneous side effects of EGFR inhibitors--appearance and management].表皮生长因子受体抑制剂的皮肤副作用——表现与处理
Dtsch Med Wochenschr. 2010 Jan;135(4):149-54. doi: 10.1055/s-0029-1244831. Epub 2010 Jan 25.
4
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
Acta Derm Venereol. 2004;84(1):23-6. doi: 10.1080/00015550310005898.
5
Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.表皮生长因子受体抑制剂西妥昔单抗的不良反应
Acta Dermatovenerol Croat. 2016 Apr;24(1):70-2.
6
Clinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 Cases.表皮生长因子受体抑制剂皮肤不良反应的临床特征：一项76例的前瞻性观察研究
Indian Dermatol Online J. 2019 May-Jun;10(3):251-255. doi: 10.4103/idoj.IDOJ_325_18.
7
Cutaneous side-effects of EGFR inhibitors and their management.表皮生长因子受体抑制剂的皮肤副作用及其处理
Skin Therapy Lett. 2011 Jan;16(1):1-3.
8
[Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].[作为表皮生长因子受体抑制剂不良反应的皮肤疹]
Ned Tijdschr Geneeskd. 2007 Apr 28;151(17):945-52.
9
A case of cicatricial alopecia associated with erlotinib.一例与厄洛替尼相关的瘢痕性脱发。
Ann Dermatol. 2011 Dec;23(Suppl 3):S350-3. doi: 10.5021/ad.2011.23.S3.S350. Epub 2011 Dec 27.
10
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
J Am Acad Dermatol. 2006 Aug;55(2):349-53. doi: 10.1016/j.jaad.2005.12.016.

引用本文的文献

1
Effects of 15% Azelaic Acid Gel in the Management of Post-Inflammatory Erythema and Post-Inflammatory Hyperpigmentation in Acne Vulgaris.15%壬二酸凝胶对寻常痤疮炎症后红斑及炎症后色素沉着的治疗效果
Dermatol Ther (Heidelb). 2024 May;14(5):1293-1314. doi: 10.1007/s13555-024-01176-2. Epub 2024 May 11.
2
Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study.定量评估帕尼单抗所致皮肤疾病：一项前瞻性观察研究。
Cancer Chemother Pharmacol. 2024 Apr;93(4):319-328. doi: 10.1007/s00280-023-04619-3. Epub 2023 Nov 28.
3
Investigation of the Mechanism of Impaired Skin Barrier Function in Dogs With Malignant Tumors.

本文引用的文献

1
International guidelines for the in vivo assessment of skin properties in non-clinical settings: Part 2. transepidermal water loss and skin hydration.国际非临床环境下皮肤特性体内评估指南：第 2 部分。经皮水分流失和皮肤水分。
Skin Res Technol. 2013 Aug;19(3):265-78. doi: 10.1111/srt.12037. Epub 2013 Jan 19.
2
Review of the treatment of non-small cell lung cancer with gefitinib.吉非替尼治疗非小细胞肺癌的疗效评价。
Clin Med Insights Oncol. 2012;6:407-21. doi: 10.4137/CMO.S7340. Epub 2012 Dec 6.
3
Improving lung cancer survival; time to move on.
恶性肿瘤犬皮肤屏障功能障碍的机制研究。
In Vivo. 2022 Mar-Apr;36(2):743-752. doi: 10.21873/invivo.12761.
4
Comparison of gefitinib-induced skin adverse reactions (SAR) in C57BL/6 and FVB/N mice.吉非替尼诱导的C57BL/6和FVB/N小鼠皮肤不良反应（SAR）的比较。
Toxicol Res (Camb). 2021 Mar 11;10(2):334-344. doi: 10.1093/toxres/tfab008. eCollection 2021 Mar.
5
Application of Zizao Yangrong Granules for Treating Targeted Drugs-Related Skin Xerosis: A Randomized Double-Blinded Controlled Study.自制药枣养荣颗粒治疗靶向药物相关性皮肤干燥症随机双盲对照研究。
Integr Cancer Ther. 2020 Jan-Dec;19:1534735420924832. doi: 10.1177/1534735420924832.
提高肺癌生存率；是时候采取行动了。
BMC Pulm Med. 2012 Dec 13;12:77. doi: 10.1186/1471-2466-12-77.
4
Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.抗表皮生长因子受体单克隆抗体和酪氨酸激酶抑制剂引起的皮肤毒性：病理生理学与管理
Chemother Res Pract. 2012;2012:351210. doi: 10.1155/2012/351210. Epub 2012 Sep 11.
5
Chemotherapy and skin reactions.化疗与皮肤反应。
J Exp Clin Cancer Res. 2012 May 28;31(1):50. doi: 10.1186/1756-9966-31-50.
6
Tumor control versus adverse events with targeted anticancer therapies.靶向抗癌治疗的肿瘤控制与不良反应。
Nat Rev Clin Oncol. 2011 Dec 20;9(2):98-109. doi: 10.1038/nrclinonc.2011.192.
7
Full-body skin mapping for six biophysical parameters: baseline values at 16 anatomical sites in 125 human subjects.全身皮肤图谱分析六个生理参数：125 名人体 16 个解剖部位的基础值。
Skin Pharmacol Physiol. 2012;25(1):25-33. doi: 10.1159/000330721. Epub 2011 Sep 7.
8
Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.表皮生长因子受体抑制剂的皮肤不良反应：14例患者的研究
An Bras Dermatol. 2011 May-Jun;86(3):483-90. doi: 10.1590/s0365-05962011000300010.
9
Dermatologic toxicities of targeted anticancer therapies.靶向抗癌疗法的皮肤毒性
J Support Oncol. 2010 Jul-Aug;8(4):149-61.
10
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼治疗的非小细胞肺癌（NSCLC）患者的皮肤病理学特征。
Eur J Cancer. 2010 Jul;46(11):2010-9. doi: 10.1016/j.ejca.2010.04.028. Epub 2010 Jun 2.